<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04086849</url>
  </required_header>
  <id_info>
    <org_study_id>087-2019</org_study_id>
    <nct_id>NCT04086849</nct_id>
  </id_info>
  <brief_title>Analysis of Patterns of Recurrence in Head and Neck Cancer Using Clinicopathomic Markers</brief_title>
  <official_title>Analysis of Patterns of Recurrence in Head and Neck Cancer Using Clinicopathomic Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Here, the investigators will develop a clinicopathomic assay from biomarkers obtained from
      digital pathologies of resected whole-mount oral cavity and oropharyngeal squamous cell
      carcinoma (OCSCC and OPSCC) specimens with the goal of administering personalized novel
      image-guided therapies immediately after primary surgical management in OCSCC and OPSCC
      patients. The primary aim is to determine the association between clinicopathomic biomarkers
      and LRR. The secondary aim is to develop a clinicopathomic risk score (assay) such that a
      decision-support tool can be used by physicians for measuring the benefit of additional
      therapies (i.e. conventional chemotherapy +/- radiation or administering dose-escalated
      chemoradiation) in the adjuvant setting to reduce LRR rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is significant for developing personalized treatments. The proposed
      research will yield high rewards to patients by providing additional information to
      clinicians for better prognostication and potentially adapting adjuvant treatments to improve
      the survival of patients with OCSCC or OPSCC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to locoregional recurrence</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Evaluating the time until a recurrence event has occurred in the oral cavity or oropharyngeal region</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to distant metastasis</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Evaluating onset of distant metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Evaluating time to cancer-related death</description>
  </secondary_outcome>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Head and Neck Neoplasm</condition>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Radiomic, pathomic, and clinical markers</intervention_name>
    <description>This is a non-interventional study.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fixed tissue samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study will enroll women and men with a pathologically-confirmed diagnosis of
        early-stage oral cavity or oropharyngeal squamous cell carcinoma that undergo surgery to
        excise the tumor.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must be men and women age 18+

          -  Confirmed diagnosis of oral cavity or oropharyngeal squamous cell carcinoma

          -  Participants must have received or will undergo surgery to excise the primary
             oropharyngeal tumor.

        Exclusion Criteria:

          -  Participants who had other primary cancers prior to oral cavity or oropharyngeal
             cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Tran, MRT(T), PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William Tran, MRT(T), PhD</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>3746</phone_ext>
    <email>william.tran@sunnybrook.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kevin Higgins, MD, FRCSC</last_name>
    <phone>416-480-5104</phone>
    <email>kalsang.sheling@sunnybrook.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Tran, MRT(T), PhD</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>3746</phone_ext>
      <email>william.tran@sunnybrook.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 10, 2019</study_first_submitted>
  <study_first_submitted_qc>September 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Dr. William Tran</investigator_full_name>
    <investigator_title>Radiation Therapist Clinician Scientist</investigator_title>
  </responsible_party>
  <keyword>radiomics</keyword>
  <keyword>pathomics</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>biomarkers</keyword>
  <keyword>machine learning</keyword>
  <keyword>artificial intelligence</keyword>
  <keyword>squamous cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All data will be anonymized. Digital pathology images and anonymized clinical data will be deposited into the National Cancer Institute (NCI) data sharing repository, including The Cancer Imaging Archive (TCIA). Digital pathology images will also be annotated to facilitate analysis for other investigators. Computational methods, source-codes and instructions will be deposited to the open-source coding repository, GitHub (www.github.com).</ipd_description>
    <ipd_time_frame>Data will be available within 12 months of study completion.</ipd_time_frame>
    <ipd_access_criteria>Digital pathology images, anonymized clinical data, source codes, and computational methods will be deposited to open-source repositories.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

